Indaptus Therapeutics Relocates HQ

Ticker: INDP · Form: 8-K · Filed: Mar 4, 2024 · CIK: 1857044

Indaptus Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyIndaptus Therapeutics, INC. (INDP)
Form Type8-K
Filed DateMar 4, 2024
Risk Levellow
Pages4
Reading Time4 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: corporate-action, administrative

TL;DR

Indaptus Therapeutics moved its HQ to NYC, formerly Intec Parent Inc.

AI Summary

On March 4, 2024, Indaptus Therapeutics, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 3 Columbus Circle, 15th Floor, New York, NY 10019. The company was formerly known as Intec Parent Inc. and changed its name on April 14, 2021.

Why It Matters

This filing signals a change in the company's operational base, which could impact its strategic direction and accessibility for investors and partners.

Risk Assessment

Risk Level: low — The filing is a routine administrative update regarding office location and former company name, with no immediate financial or operational risks disclosed.

Key Players & Entities

FAQ

What is the new address for Indaptus Therapeutics, Inc.'s principal executive offices?

The new address for Indaptus Therapeutics, Inc.'s principal executive offices is 3 Columbus Circle, 15th Floor, New York, NY 10019.

When did Indaptus Therapeutics, Inc. change its name?

Indaptus Therapeutics, Inc. changed its name on April 14, 2021.

What was Indaptus Therapeutics, Inc.'s former company name?

Indaptus Therapeutics, Inc.'s former company name was Intec Parent Inc.

What is the filing date of this Form 8-K?

The filing date of this Form 8-K is March 4, 2024.

In which state was Indaptus Therapeutics, Inc. incorporated?

Indaptus Therapeutics, Inc. was incorporated in Delaware.

Filing Stats: 1,118 words · 4 min read · ~4 pages · Grade level 18.2 · Accepted 2024-03-04 11:01:33

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 4, 2024 INDAPTUS THERAPEUTICS, INC. By: /s/ Nir Sassi Name: Nir Sassi Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing